Imugene Limited (ASX: IMU) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Imugene Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Imugene Limited (ASX: IMU)
Latest News
Share Gainers
Why the Imugene (ASX:IMU) share price is charging higher on Thursday
Share Fallers
Why AVZ Minerals, Imugene, Pointerra, & Resolute shares are dropping
Share Market News
Capital keeps flowing into ASX Biotech shares in 2021
Share Fallers
Why BARD1, Imugene, Northern Star, & Silver Lake shares are sinking
⏸️ ASX Shares
The 5 best ASX shares of FY21 revealed
Healthcare Shares
The 5 best performing ASX healthcare shares of FY21, did yours make the cut?
Healthcare Shares
How these top ASX biotech shares performed in FY21
Share Gainers
Why a2 Milk, Chalice Mining, IDP Education, & Imugene are charging higher
Best Shares
Here are the 5 best performing ASX All Ords shares from FY21
Share Gainers
Imugene (ASX:IMU) share price jumps 8% on FDA update
Share Gainers
These 3 ASX biotech shares are all up at least 120% in a year
Share Market News
NAB and Zip were among the most traded ASX shares last week
Frequently Asked Questions
-
Imugene does not pay dividends at this stage.
-
Imugene Ltd (ASX: IMU) listed on the ASX on 24 November 1993.
IMU ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Imugene Limited
Imugene Ltd (ASX: IMU) is a biotechnology company working in cancer immunotherapy.
The company specialises in clinical-stage immuno-oncology therapies. Its product pipeline includes Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard-care drugs and immunotherapies.
The company's lead product is HER-Vaxx, a proprietary cancer vaccine for the treatment of gastric and breast cancer, where the cancer is HER-2 positive. The vaccine has demonstrated it stimulates a polyclonal antibody response to HER2/neu.
Imugene's various immunotherapy products are involved in ongoing clinical trials involving cancer specialists and researchers worldwide.
